Interv Akut Kardiol. 2010;9(6):310-315

Dronedarone - new antiarrhythmic drug for treatment of atrial fibrillation

Kateřina Lefflerová
Klinika kardiologie IKEM, Praha

Dronedarone is new antiarrhythmic agent developed for the treatment of atrial fibrillation. It is a noniodinated benzofuran derivate of

amiodarone with electrophysiological properties similar to amiodarone but without pulmonary and thyreoid toxicity. Dronedarone has

been proven to maintain sinus rhythm and to control ventricular rate during episodes of atrial fibrillation. Patients with severe heart

failure should not receive dronedarone. It si a first antiarrhythmic drug, which reduced cardiovascular hospitalisation and mortality.

Keywords: atrial fibrillation, antiarrhythmic drugs, dronedarone, hospitalization, mortality

Published: December 10, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lefflerová K. Dronedarone - new antiarrhythmic drug for treatment of atrial fibrillation. Interv Akut Kardiol. 2010;9(6):310-315.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. Go to original source... Go to PubMed...
    2. Gersh BJ, Tsang TSM, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Transactions Am Clin Climatol Assoc 2004; 116: 149-160.
    3. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
    4. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677. Go to original source... Go to PubMed...
    5. Čihák R, Heinc P. Doporučení pro léčbu pacientů s fibrilací síní. CorVasa 2004; 46(5): K67-77.
    6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745. Go to original source... Go to PubMed...
    7. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513. Go to original source... Go to PubMed...
    8. Wyse DG, Slee A, EpsteinAE, et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm 2004; 1: 531-537. Go to original source... Go to PubMed...
    9. Falk RH, Camm AJ. Rethinking in reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations. Eur Heart J 2009; 30: 2438-2440. Go to original source... Go to PubMed...
    10. Roy D, Talajic M, Dorian P, et al. for the Canadian Trial of Atrial Fibrillation Investigators: Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920. Go to original source... Go to PubMed...
    11. Čihák R. Dronedaron. Remedia 2006; 4: 443-446.
    12. Lefflerová K. Dronedaron ve světle nových klinických studií. Remedia 2009; 19: 390-393.
    13. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64: 785-791. Go to original source... Go to PubMed...
    14. Toubol P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose ranging study. Eur Heart J 2003; 24: 1481-1487. Go to original source... Go to PubMed...
    15. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-999. Go to original source... Go to PubMed...
    16. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for the control of ventricular rate during atrial fibrillation (ERATO study). Am Heart J 2008; 156: 527-529. Go to original source... Go to PubMed...
    17. Kober L, Torp-Pedersen C, McMurray JV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687. Go to original source... Go to PubMed...
    18. Hohnloser SH, Crijns HJ, van Eickels M, et al. for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678. Go to original source... Go to PubMed...
    19. Duray GZ, Schmitt J, Hohnloser SH. Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials. J Cardiovasc Pharmacol Ther 2010; DOI10.1177/1074248410368530. Go to original source... Go to PubMed...
    20. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg bid for prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120: 1174-1180. Go to original source... Go to PubMed...
    21. Lip GYH, Frison L, Grind M. on behalf of the SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28: 752-759. Go to original source... Go to PubMed...
    22. Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxid in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart. Eur J Pharmacol 2004; 496: 119-127. Go to original source... Go to PubMed...
    23. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54: 1089-1095. Go to original source... Go to PubMed...
    24. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597-605. Go to original source... Go to PubMed...
    25. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010; 375: 1212-1123. Go to original source... Go to PubMed...
    26. Torp-Pedresen C, Pedersen OD, Kober L. Antiarrhythmic drugs. Safety first. J Am Coll Cardiol 2010; 55: 1577-1579. Go to original source... Go to PubMed...
    27. Naccarelli GV, Gonzales MD. Atrial fibrillation and the expanding role of catheter ablation: Do antiarrhythmic drugs have a future? J Cardiovasc Pharmacol(TM) 2008; 52: 203-209. Go to original source... Go to PubMed...
    28. Singh D, Cingolani E, Diamond GA, et al. Dronedarone for atrial fibrillation. Have we expanded antiarrhythmic armamentarium? J Am Coll Cardiol 2010; 55: 1569-1576. Go to original source... Go to PubMed...
    29. NICE guidance on the use of dronedarone for treating atrial fibrillation. www.nice.org.uk/guidance/TA197.
    30. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal 2010; doi 10.1093/eurheartj/ehq 278.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.